Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment‐Naive Subjects with HIV‐1 Infection | Zendy

Raphael J. Landovitz | Zendy; Jonathan B. Angel | Zendy; Christian Hoffmann | Zendy; Heinz A. Horst | Zendy; Milos Opravil | Zendy; Jianmin Long | Zendy; Wayne Greaves | Zendy; Gerd Fätkenheuer | Zendy

Open Access

Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment‐Naive Subjects with HIV‐1 Infection

Author(s) -

Raphael J. Landovitz,

Jonathan B. Angel,

Christian Hoffmann,

Heinz A. Horst,

Milos Opravil,

Jianmin Long,

Wayne Greaves,

Gerd Fätkenheuer

Publication year - 2008

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/592052

Subject(s) - lamivudine , zidovudine , efavirenz , placebo , medicine , reverse transcriptase inhibitor , gastroenterology , immunology , viral load , pharmacology , human immunodeficiency virus (hiv) , viral disease , virus , antiretroviral therapy , hepatitis b virus , pathology , alternative medicine

Vicriviroc (VCV) is a CCR5 antagonist with nanomolar activity against human immunodeficiency virus (HIV) replication in vitro and in vivo. We report the results of a phase II dose-finding study of VCV plus dual nucleoside reverse-transcriptase inhibitors (NRTIs) in the treatment-naive HIV-1-infected subjects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research